Doxorubicin pretreatment enhances FAPα/survivin co-targeting DNA vaccine anti-tumor activity primarily through decreasing peripheral MDSCs in the 4T1 murine breast cancer model-Reference-Cited by-同舟云学术

Doxorubicin pretreatment enhances FAPα/survivin co-targeting DNA vaccine anti-tumor activity primarily through decreasing peripheral MDSCs in the 4T1 murine breast cancer model

Published:2020-01-01 Issue:1 Volume:9 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Geng Fei¹,Bao Xin¹,Dong Ling¹,Guo Qian-Qian¹,Guo Jie¹,Xie Yu¹,Zhou Yi¹,Yu Bin¹,Wu Hui¹,Wu Jia-Xin¹,Zhang Hai-Hong¹²,Yu Xiang-Hui¹²,Kong Wei¹²

Affiliation:

1. National Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun, P. R. China

2. Key Laboratory for Molecular Enzymology and Engineering, the Ministry of Education, School of Life Sciences, Jilin University, Changchun, P. R. China

Funder

Key R & D Projects of Science and Technology Department of Jilin Province

Major Projects of Science and Technology Innovation

National Science and Technology Major Project of the Ministry of Science and Technology of China

Jilin Province Science and Technology Development Program

Specialized Research Fund for the National Natural Science Foundation of China

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2020.1747350